ClinicalTrials.gg
CompletedNCT02616029Updated Jul 23, 2020Results posted

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

A Phase 3 interventional study of E/C/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-23.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) plus a third antiretroviral (ARV) agent in participants harboring the archived nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance mutation M184V and/or M184I in human immunodeficiency virus (HIV) -1 reverse transcriptase.

This is a two part study. If the rate of virologic failure in Part 1 is deemed acceptable, once the internal data monitoring committee officially completes the interim review, the study will continue to Part 2.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented historical genotype report showing mutation M184V and/or M184I (mixtures are acceptable) in reverse transcriptase. Individuals must not have any primary integrase strand transfer inhibitor (INSTI) or primary protease inhibitor (PI) resistance mutations present on historical genotype; non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations are allowed.
  • Proviral deoxyribonucleic acid (DNA) test must not have additional exclusion resistance mutations against PIs, NRTIs and INSTIs

    • Part 1: Historical genotype report must show mutation M184V and/or M184I in reverse transcriptase WITHOUT any other NRTI resistance mutation (including thymidine analogue-associated mutations [TAMs] [TAMs are: M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E/N/R], K65R, K70E, T69 insertion, and Q151M mutation complex [A62V, V75I, F77L, F116Y, Q151M])
    • Part 2 (after the interim efficacy review): Historical genotype report must show M184V and/or M184I in reverse transcriptase WITH or WITHOUT 1 or 2 TAMs. Evidence of K65R, K70E, T69 insertion and/or Q151M mutation complex will not be eligible
  • Currently receiving an ARV regimen consisting of FTC/TDF or ABC/3TC in combination with one third ARV agent for ≥ 6 consecutive months preceding the screening visit
  • Documented plasma -1 ribonucleic acid (RNA) levels \< 50 copies/mL for ≥ 6 months preceding the screening visit
  • Plasma HIV-1 RNA levels \< 50 copies/mL at screening visit
  • Estimated (GFR) ≥ 30 mL/min according to the formula for creatinine clearance
  • A female individual is eligible to enter the study if it is confirmed that she is:

    • not pregnant
    • of non-
    • stopped menstruating for ≥ 12 months
    • of childbearing potential and agrees to utilize the protocol-specified method of or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following discontinuation of study drugs
  • Male individuals must agree to use the protocol-specified method(s) of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from screening throughout the study period and for 30 days following the last study drug dose

    • Male individuals must agree to refrain from sperm donation from first dose until at least 30 days after the last study drug dose

Key Exclusion Criteria:

  • Individuals will have no evidence of previous virologic failure on a PI/r or INSTI-based regimen (with or without resistance to either class of ARV). Individuals may have evidence of prior virologic failure on only an NNRTI plus 2 NRTI-based regimen
  • Individuals on a current PI/r-based regimen will have no evidence of previous use of any approved or experimental integrase strand transfer inhibitor (INSTI) (for any length of time)
  • infection that would require therapy during the study
  • surface antigen (HBsAg) positive
  • Individuals with clinical evidence of decompensated cirrhosis (eg, ascites, encephalopathy, variceal bleeding)
  • Have an implanted defibrillator or pacemaker
  • A history of within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non invasive cutaneous squamous carcinoma. Individuals with cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Day 1 and must not be anticipated to require systemic therapy during the study
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Part 1: E/C/F/TAF

    Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks. Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG).

    Drug: E/C/F/TAF

  • Experimental
    Part 2: E/C/F/TAF

    Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks. Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG.

    Drug: E/C/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)

    The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 12 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With Emergence of New Mutations in HIV-1 Reverse Transcriptase and Integrase

    Development of new resistance mutations was assessed in participants who developed virologic failure, defined as 2 consecutive HIV-1 RNA result ≥ 50 copies/mL at any point in the study or with HIV-1 RNA ≥ 50 copies/mL at last visit.

    Time frame: Day 1 up to 48 weeks

  2. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using PVR

    The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 24 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.

    Time frame: Week 24

  3. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using PVR

    The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.

    Time frame: Week 48

  4. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).

    Time frame: Week 12

  5. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).

    Time frame: Week 24

  6. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).

    Time frame: Week 48

  7. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 12 Using the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).

    Time frame: Week 12

  8. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 24 Using the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).

    Time frame: Week 24

  9. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 Using the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).

    Time frame: Week 48

  10. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Failure (M = F) Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 12

  11. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = F Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 24

  12. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = F Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 48

  13. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Excluded (M = E) Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

    Time frame: Week 12

  14. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = E Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

    Time frame: Week 24

  15. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

    Time frame: Week 48

  16. Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 12

    Time frame: Baseline (Day 1); Week 12

  17. Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline (Day 1); Week 24

  18. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline (Day 1); Week 48

  19. Change From Baseline in CD4 Percentage (%) at Week 12

    Time frame: Baseline (Day 1); Week 12

  20. Change From Baseline in CD4 % at Week 24

    Time frame: Baseline (Day 1); Week 24

  21. Change From Baseline in CD4 % at Week 48

    Time frame: Baseline (Day 1); Week 48

07

Results

Posted Nov 4, 2019

Participant flow

Participants were enrolled at study sites in the United States and Europe. The first participant was screened on 17 December 2015. The last study visit occurred on 11 July 2019.

Participant flow — Overall Study
MilestonePart 1: E/C/F/TAFPart 2: E/C/F/TAF
Started3828
Completed3426
Not completed42
Withdrew: Adverse event10
Withdrew: Death01
Withdrew: Protocol violation10
Withdrew: Withdrew consent10
Withdrew: Enrolled and never treated11

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)

The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 12 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)100.0 (90.3 to 100.0)100.0 (86.8 to 100.0)100.0 (94.2 to 100.0)
SecondaryPercentage of Participants With Emergence of New Mutations in HIV-1 Reverse Transcriptase and Integrase

Development of new resistance mutations was assessed in participants who developed virologic failure, defined as 2 consecutive HIV-1 RNA result ≥ 50 copies/mL at any point in the study or with HIV-1 RNA ≥ 50 copies/mL at last visit.

Time frame:
Day 1 up to 48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Emergence of New Mutations in HIV-1 Reverse Transcriptase and Integrase
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With Emergence of New Mutations in HIV-1 Reverse Transcriptase and Integrase000
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using PVR

The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 24 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using PVR
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using PVR100.0 (90.3 to 100.0)100.0 (86.8 to 100.0)100.0 (94.2 to 100.0)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using PVR

The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using PVR
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using PVR100.0 (90.3 to 100.0)100.0 (86.8 to 100.0)100.0 (94.2 to 100.0)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the FDA Snapshot Analysis
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the FDA Snapshot Analysis91.7 (77.5 to 98.2)96.2 (80.4 to 99.9)93.5 (84.3 to 98.2)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the FDA Snapshot Analysis
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the FDA Snapshot Analysis91.7 (77.5 to 98.2)100.0 (86.8 to 100.0)95.2 (86.5 to 99.0)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA Snapshot Analysis
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA Snapshot Analysis88.9 (73.9 to 96.9)96.2 (80.4 to 99.9)91.9 (82.2 to 97.3)
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 12 Using the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 12 Using the FDA Snapshot Analysis
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 12 Using the FDA Snapshot Analysis91.7 (77.5 to 98.2)96.2 (80.4 to 99.9)93.5 (84.3 to 98.2)
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 24 Using the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 24 Using the FDA Snapshot Analysis
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 24 Using the FDA Snapshot Analysis88.9 (73.9 to 96.9)100.0 (86.8 to 100.0)93.5 (84.3 to 98.2)
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 Using the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 Using the FDA Snapshot Analysis
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 Using the FDA Snapshot Analysis88.9 (73.9 to 96.9)96.2 (80.4 to 99.9)91.9 (82.2 to 97.3)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Failure (M = F) Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Failure (M = F) Approach
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Failure (M = F) Approach97.2 (85.5 to 99.9)96.2 (80.4 to 99.9)96.8 (88.8 to 99.6)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = F Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = F Approach
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = F Approach91.7 (77.5 to 98.2)100.0 (86.8 to 100.0)95.2 (86.5 to 99.0)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = F Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = F Approach
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = F Approach91.7 (77.5 to 98.2)96.2 (80.4 to 99.9)93.5 (84.3 to 98.2)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Excluded (M = E) Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Excluded (M = E) Approach
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Excluded (M = E) Approach100.0 (90.0 to 100.0)96.2 (80.4 to 99.9)98.4 (91.2 to 100.0)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = E Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = E Approach
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = E Approach100.0 (89.4 to 100.0)100.0 (86.8 to 100.0)100.0 (93.9 to 100.0)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach
percentage of participantsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach100.0 (89.4 to 100.0)100.0 (86.3 to 100.0)100.0 (93.8 to 100.0)
SecondaryChange From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 12
Time frame:
Baseline (Day 1); Week 12
Reported as:
Mean · cells/µL
Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 12
cells/µLPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 12-47 ± 194.1-6 ± 116.1-30 ± 165.1
SecondaryChange From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline (Day 1); Week 24
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 24
cells/µLPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Change From Baseline in CD4+ Cell Count at Week 24-40 ± 162.128 ± 212.5-10 ± 187.4
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline (Day 1); Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Change From Baseline in CD4+ Cell Count at Week 48-6 ± 131.927 ± 120.49 ± 126.8
SecondaryChange From Baseline in CD4 Percentage (%) at Week 12
Time frame:
Baseline (Day 1); Week 12
Reported as:
Mean · percentage of CD4 cells
Change From Baseline in CD4 Percentage (%) at Week 12
percentage of CD4 cellsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Change From Baseline in CD4 Percentage (%) at Week 12-0.4 ± 3.371.5 ± 3.010.4 ± 3.33
SecondaryChange From Baseline in CD4 % at Week 24
Time frame:
Baseline (Day 1); Week 24
Reported as:
Mean · percentage of CD4 cells
Change From Baseline in CD4 % at Week 24
percentage of CD4 cellsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Change From Baseline in CD4 % at Week 240.1 ± 3.251.1 ± 4.300.5 ± 3.75
SecondaryChange From Baseline in CD4 % at Week 48
Time frame:
Baseline (Day 1); Week 48
Reported as:
Mean · percentage of CD4 cells
Change From Baseline in CD4 % at Week 48
percentage of CD4 cellsPart 1: E/C/F/TAFPart 2: E/C/F/TAFTotal E/C/F/TAF
Change From Baseline in CD4 % at Week 480.2 ± 3.121.5 ± 3.640.8 ± 3.39

Adverse events

Collected over First dose date up to the last dose date (maximum: 48 Weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total E/C/F/TAF1/64 (1.6%)5/64 (7.8%)26/64 (40.6%)
Most frequent serious events
Most frequent serious events
EventTotal E/C/F/TAF
DeathGeneral disorders1/64
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/64
Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/64
Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/64
Acute kidney injuryRenal and urinary disorders1/64
ProteinuriaRenal and urinary disorders1/64
Renal failureRenal and urinary disorders1/64
Most frequent other events
Most frequent other events
EventTotal E/C/F/TAF
AstheniaGeneral disorders7/64
BronchitisInfections and infestations7/64
NasopharyngitisInfections and infestations7/64
HeadacheNervous system disorders6/64
DiarrhoeaGastrointestinal disorders5/64
Back painMusculoskeletal and connective tissue disorders5/64
CoughRespiratory, thoracic and mediastinal disorders5/64
DizzinessNervous system disorders4/64

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
Mean50 ± 9.252 ± 9.551 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
Female8917
Male291847
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
Ethnicity — Hispanic or Latino6410
Ethnicity — Not Hispanic or Latino272148
Ethnicity — Not Permitted426
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
Race — American Indian or Alaska Native000
Race — Asian000
Race — Black7815
Race — Native Hawaiian or Pacific Islander000
Race — White271744
Race — Not Permitted325
Region of Enrollment
Region of Enrollment(Participants)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
United States358
Italy235
France141529
Germany415
Spain14317
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
Mean1.29 ± 0.0561.29 ± 0.0461.29 ± 0.052
HIV-1 RNA Categories
HIV-1 RNA Categories(Participants)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
< 50 copies/mL372764
≥ 50 copies/mL000
Cluster Determinant 4+ (CD4+) Cell Count
Cluster Determinant 4+ (CD4+) Cell Count(cells/µL)Part 1: E/C/F/TAFPart 2: E/C/F/TAFTotal
Mean740 ± 319.6665 ± 312.7708 ± 316.4

3 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • Midway Immunology & Research Center, LLC
    Fort Pierce, Florida 34982, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida 33407, United States
  • Hopital Sainte Marguerite - Hospital
    Marseille, 13009, France
  • CHU de Nantes
    Nantes, 44093, France
  • CHU de Nice-l Archet
    Nice, 06202, France
  • CHR Orleans la Source
    Orleans, 45000, France
  • Hopital Saint Louis
    Paris Cedex 10, 75010, France
  • Hopital Necker les Enfants Malades
    Paris Cedex 15, 75015, France
  • CHU Tours Service de Médecine Internes et Maladies Infectieuses
    Tours, 37044, France
  • Universitatsklinikum Essen
    Essen, 45147, Germany
  • ICH Study Center- Dedicated Research
    Hamburg, 20146, Germany
  • Universitat Mainz
    Mainz, 55131, Germany
  • IRCCS A.O.U. San Martino
    Genova, 16132, Italy
  • Fondazione IRCCS San Raffaele del Monte Tabor
    Milano, 20132, Italy
  • ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco
    Milano, 20157, Italy
  • Comprensorio Amedeo Di Savoia Birago Di Vische
    Torino, 10149, Italy
  • Hospital Universitari Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital Clinic de Barcelona - Hospital
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre - Hospital
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
09

References and documents

Publications

  • Perez-Valero I, Llibre JM, Lazzarin A, di Perri G, Pulido F, Molina JM, Esser S, Margot N, Shao Y, Piontkowsky D, Das M, McNicholl IR, Haubrich R. A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V/I (GS-US-292-1824): Week 24 Results [Poster PE13/20]. 17th European AIDS Conference (EACS), 6-9 November 2019, Basel, Switzerland.
  • Perez-Valero I, Llibre JM, Lazzarin A, di Perri G, Pulido F, Molina JM, Esser S, McNicholl IR, Lorgeoux RP, Margot N, Shao Y, Piontkowsky D, Das M, Haubrich R. A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824): Week 24 Results [Oral abstract]. 22nd International AIDS Conference, 23-27 July 2018, Amsterdam, The Netherlands.
  • Perez-Valero I, Llibre JM, Lazzarin A, di Perri G, Pulido F, Molina JM, Esser S, McNicholl IR, Lorgeoux RP, Margot N, Shao Y, Piontkowsky D, Das M, Haubrich R. A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824): Week 12 Results [Poster]. XXVI International Workshop on HIV Drug Resistance and Treatment Strategies, 6-8 November 2017, Johannesburg, South Africa.
  • Perez-Valero I, Llibre JM, Castagna A, Pulido F, Molina JM, Esser S, Margot N, Shao Y, Temme L, Piontkowsky D, McNicholl IR, Haubrich R. Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):490-495. doi: 10.1097/QAI.0000000000002595. PubMed 33315694 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Oct 2018, 33 months.

Results were first posted in Nov 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2015
First posted
Nov 26, 2015
StartActual
Dec 17, 2015
Primary completionActual
Oct 11, 2018
CompletionActual
Jul 11, 2019
Results first posted
Nov 4, 2019
Last update
Jul 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02616029
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 26, 2015
Start date
Dec 17, 2015
Primary completion
Oct 11, 2018
Completion
Jul 11, 2019
Results posted
Nov 4, 2019
Last update
Jul 23, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion